NDAORALTABLET
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOQUEZNA (vonoprazan fumarate) is an oral potassium-competitive acid blocker (PCAB) approved by the FDA in July 2024 for acid-related gastrointestinal disorders. It represents a novel mechanism class distinct from traditional proton pump inhibitors (PPIs), offering faster onset and potentially superior acid suppression. The drug is indicated for conditions requiring gastric acid reduction in adult patients.
Growth
As a recently approved product in growth phase, VOQUEZNA brand teams are ramping commercial infrastructure with moderate competitive intensity, indicating active hiring and team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.
Started Oct 2023
30 enrolled
Gastric Ulcer
Career Relevance
VOQUEZNA currently shows limited job openings (1 linked position) dominated by entry-level roles, reflecting the early post-approval phase where core teams are smaller and specialized. As the product moves through its growth phase, expect expansion in commercial, medical affairs, and market access roles over the next 12-24 months.
Intern
Worked on VOQUEZNA at Phathom Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.